WO2005067913A1 - リパーゼ阻害剤 - Google Patents
リパーゼ阻害剤 Download PDFInfo
- Publication number
- WO2005067913A1 WO2005067913A1 PCT/JP2004/019360 JP2004019360W WO2005067913A1 WO 2005067913 A1 WO2005067913 A1 WO 2005067913A1 JP 2004019360 W JP2004019360 W JP 2004019360W WO 2005067913 A1 WO2005067913 A1 WO 2005067913A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- triacylglycerol
- active ingredient
- carbon atoms
- type
- chain
- Prior art date
Links
- 229940086609 Lipase inhibitor Drugs 0.000 title claims abstract description 21
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 37
- 239000004480 active ingredient Substances 0.000 claims abstract description 30
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000000126 substance Substances 0.000 claims abstract description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 14
- 150000003626 triacylglycerols Chemical class 0.000 claims abstract description 14
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract description 11
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims abstract description 11
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 10
- 150000004666 short chain fatty acids Chemical class 0.000 claims abstract description 10
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical class OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 8
- 150000004668 long chain fatty acids Chemical class 0.000 claims abstract description 8
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 60
- -1 glyceryl ether lipid Chemical class 0.000 claims description 26
- 235000013305 food Nutrition 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- 238000010521 absorption reaction Methods 0.000 claims description 20
- 150000002632 lipids Chemical class 0.000 claims description 15
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 13
- 229930195729 fatty acid Natural products 0.000 claims description 13
- 239000000194 fatty acid Substances 0.000 claims description 13
- 150000004665 fatty acids Chemical class 0.000 claims description 13
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 235000011187 glycerol Nutrition 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 10
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 10
- 239000000883 anti-obesity agent Substances 0.000 claims description 9
- 229940125710 antiobesity agent Drugs 0.000 claims description 9
- 235000021391 short chain fatty acids Nutrition 0.000 claims description 4
- 239000003925 fat Substances 0.000 abstract description 50
- 239000003921 oil Substances 0.000 abstract description 44
- 108090001060 Lipase Proteins 0.000 abstract description 32
- 239000004367 Lipase Substances 0.000 abstract description 32
- 102000004882 Lipase Human genes 0.000 abstract description 32
- 235000019421 lipase Nutrition 0.000 abstract description 32
- 230000007062 hydrolysis Effects 0.000 abstract description 18
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 18
- 208000008589 Obesity Diseases 0.000 abstract description 13
- 235000020824 obesity Nutrition 0.000 abstract description 13
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 3
- 235000019197 fats Nutrition 0.000 description 47
- 235000019198 oils Nutrition 0.000 description 43
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 29
- 238000012360 testing method Methods 0.000 description 25
- 239000000203 mixture Substances 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- 239000003549 soybean oil Substances 0.000 description 19
- 235000012424 soybean oil Nutrition 0.000 description 19
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 18
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 12
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 12
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 11
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 11
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 11
- 239000005642 Oleic acid Substances 0.000 description 11
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 11
- 230000029087 digestion Effects 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 11
- 235000019626 lipase activity Nutrition 0.000 description 11
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 235000005911 diet Nutrition 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 235000021357 Behenic acid Nutrition 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 210000000577 adipose tissue Anatomy 0.000 description 9
- 229940116226 behenic acid Drugs 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 235000014593 oils and fats Nutrition 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000019634 flavors Nutrition 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000008117 stearic acid Substances 0.000 description 8
- 235000021355 Stearic acid Nutrition 0.000 description 7
- 238000004821 distillation Methods 0.000 description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 7
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 235000021314 Palmitic acid Nutrition 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 6
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
- 229940127470 Lipase Inhibitors Drugs 0.000 description 5
- 108010048733 Lipozyme Proteins 0.000 description 5
- 244000269722 Thea sinensis Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 239000011630 iodine Substances 0.000 description 5
- FCCDDURTIIUXBY-UHFFFAOYSA-N lipoamide Chemical compound NC(=O)CCCCC1CCSS1 FCCDDURTIIUXBY-UHFFFAOYSA-N 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 235000013616 tea Nutrition 0.000 description 5
- 238000005809 transesterification reaction Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 4
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 4
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 4
- 230000003631 expected effect Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 4
- 235000019871 vegetable fat Nutrition 0.000 description 4
- 235000019737 Animal fat Nutrition 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 235000019484 Rapeseed oil Nutrition 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 235000019219 chocolate Nutrition 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N linoleic acid group Chemical group C(CCCCCCC\C=C/C\C=C/CCCCC)(=O)O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000013310 margarine Nutrition 0.000 description 3
- 235000010746 mayonnaise Nutrition 0.000 description 3
- 239000008268 mayonnaise Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 235000020991 processed meat Nutrition 0.000 description 3
- 230000000384 rearing effect Effects 0.000 description 3
- 235000013580 sausages Nutrition 0.000 description 3
- 239000010686 shark liver oil Substances 0.000 description 3
- 229940069764 shark liver oil Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 125000003203 triacylglycerol group Chemical group 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- STTGYIUESPWXOW-UHFFFAOYSA-N 2,9-dimethyl-4,7-diphenyl-1,10-phenanthroline Chemical compound C=12C=CC3=C(C=4C=CC=CC=4)C=C(C)N=C3C2=NC(C)=CC=1C1=CC=CC=C1 STTGYIUESPWXOW-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000251730 Chondrichthyes Species 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 244000020551 Helianthus annuus Species 0.000 description 2
- 235000003222 Helianthus annuus Nutrition 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000002199 base oil Substances 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000828 canola oil Substances 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- XTVVROIMIGLXTD-UHFFFAOYSA-N copper(II) nitrate Chemical compound [Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O XTVVROIMIGLXTD-UHFFFAOYSA-N 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- JIZCYLOUIAIZHQ-UHFFFAOYSA-N ethyl docosenyl Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC JIZCYLOUIAIZHQ-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 239000003778 fat substitute Substances 0.000 description 2
- 235000013341 fat substitute Nutrition 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000001087 glyceryl triacetate Substances 0.000 description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003264 margarine Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002454 metastable transfer emission spectrometry Methods 0.000 description 2
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 235000014214 soft drink Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 239000003760 tallow Substances 0.000 description 2
- 229960002622 triacetin Drugs 0.000 description 2
- CPUDPFPXCZDNGI-UHFFFAOYSA-N triethoxy(methyl)silane Chemical compound CCO[Si](C)(OCC)OCC CPUDPFPXCZDNGI-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical group OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- 240000006914 Aspalathus linearis Species 0.000 description 1
- 235000012984 Aspalathus linearis Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241001454694 Clupeiformes Species 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000055850 Diospyros virginiana Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000001653 FEMA 3120 Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 241001502129 Mullus Species 0.000 description 1
- AHLBNYSZXLDEJQ-UHFFFAOYSA-N N-formyl-L-leucylester Natural products CCCCCCCCCCCC(OC(=O)C(CC(C)C)NC=O)CC1OC(=O)C1CCCCCC AHLBNYSZXLDEJQ-UHFFFAOYSA-N 0.000 description 1
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000907246 Pastilla Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 239000007994 TES buffer Substances 0.000 description 1
- 235000004552 Yucca aloifolia Nutrition 0.000 description 1
- 244000116042 Yucca brevifolia Species 0.000 description 1
- 235000012044 Yucca brevifolia Nutrition 0.000 description 1
- 235000017049 Yucca glauca Nutrition 0.000 description 1
- 244000131415 Zanthoxylum piperitum Species 0.000 description 1
- 235000008853 Zanthoxylum piperitum Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 235000019513 anchovy Nutrition 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000741 diarrhetic effect Effects 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- AZHSSKPUVBVXLK-UHFFFAOYSA-N ethane-1,1-diol Chemical compound CC(O)O AZHSSKPUVBVXLK-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 235000021097 low calorie intake Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 235000013446 pixi Nutrition 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000020330 rooibos tea Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 241001223854 teleost fish Species 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000020334 white tea Nutrition 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical group O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
- C11C3/04—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fats or fatty oils
- C11C3/10—Ester interchange
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a lipase inhibitor and a food containing the same. More specifically, the safety of spleen lipase, which is a key to obesity and hyperlipidemia, which can inhibit the digestion and absorption of lipids in vivo and contribute to the suppression and prevention of these diseases. It relates to lipase inhibitors with high oil solubility. Background art
- lipase inhibitors there is a need to develop a drug that inhibits and prevents fat overload by increasing the amount of lipid intake by reducing the digestion and absorption by partially inhibiting the degradation of ingested lipids by spleen lipase in the duodenum. It has been tried in recent years. With this concept, there is no particular restriction on the type and amount of fats and oils contained in foods, and it is expected that calories can be reduced without impairing the flavor level of existing foods.
- Patent Document 1 Iwabenkei, Sabonso, Bonoredo, Pastilla, Tormentilla, Enorecampuri, Konkonsomatsu, Chuchuashia, Jacklow, Cinnamon, Sansho, Sendangsa, Sokoggi, Stomachi Berry, Moje, Rose, Persimmon, Seiyotogirisou, Tochu and White Tea
- a lipase inhibitor containing at least one member selected from the group has been proposed.
- Patent Document 2 extraction from at least one or more types of materials selected from the group consisting of yucca, ginseng, jasmine tea, Yamashiko, Huangkai tea, rooibos tea, soybean germ, ginger, and Tochu tea is described.
- a lipase inhibitor containing an extract as an active ingredient has been proposed.
- Patent Document 3 proposes to use tetrahydrolipstatin as a gastrointestinal lipase inhibitor. It is said that this inhibitor directly inactivates lipase by directly covalently binding to lipase itself, and its effect is quite potent, with some diarrheal symptoms observed, and concerns about the safety of food remain. An oil-soluble lipase inhibitor that exerts a milder effect is desired.
- Patent Document 1 Japanese Patent Application Laid-Open No. 2002-179586
- Patent Document 2 JP-A-2002-275077
- Patent Document 3 U.S. Patent No.
- An object of the present invention is to contribute to prevention and treatment of obesity due to excessive intake of fat and diseases caused by obesity, and to inhibit hydrolysis by lipase by adding to all kinds of fats and oils. It is an object of the present invention to provide an oil-soluble lipase inhibitor.
- SLS-type triacylglycerol S is a short-chain fatty acid having 2 to 6 carbon atoms
- L Are symmetric triacylglycerols composed of long-chain fatty acids having 16-22 carbon atoms
- LUU-type and UUL-type triacylglycerols L is a long-chain saturated fatty acid having 16-22 carbon atoms
- U is Asymmetric triacylglycerol composed of unsaturated fatty acids having 16 to 22 carbon atoms
- glyceryl ether lipid in which a long alkyl chain or alkenyl chain is ether-bonded to the first or third position of glycerin.
- the first aspect of the present invention is an oil-soluble substance, wherein SLS-type triacylglycerol is a short-chain fatty acid having 2 to 6 carbon atoms, and L is a symmetric tria composed of a long-chain fatty acid having 16 to 22 carbon atoms.
- Silglycerol LUU-type and UUL-type triacylglycerol (L is a long-chain saturated fatty acid having 16 to 22 carbon atoms, U is an asymmetric triacylglycerol composed of an unsaturated fatty acid having 16 to 22 carbon atoms) or A lipase inhibitor comprising, as an active ingredient, at least one substance selected from glyceryl ether lipids having a long alkyl chain or an alkenyl chain at the first or third position of glycerin.
- the selected oil-soluble substance described in 1 is SLS-type triacylglycerol (where S is a short-chain fatty acid having 2 to 6 carbon atoms and L is a long-chain fatty acid having 16 to 22 carbon atoms) (Triacylglycerol) as an active ingredient.
- S is a short-chain fatty acid having 2 to 6 carbon atoms and L is a long-chain fatty acid having 16 to 22 carbon atoms
- Triacylglycerol Triacylglycerol
- a lipid absorption inhibitor containing the SLS-type triacylglycerol described in the second as an active ingredient.
- an anti-obesity agent containing the SLS-type triacylglycerol described in the second item as an active ingredient.
- a hyperlipidemia-ameliorating agent comprising the SLS-type triacylglycerol described in the second item as an active ingredient.
- Sixth is a food containing the agent according to any one of the second to fifth aspects.
- Seventh is a medicament containing the agent according to any one of the second to fifth aspects.
- Eighth is the oil-soluble substance selected from LUU-type and UUL-type triacylglycerol described in 1 (L is a long-chain saturated fatty acid having 16 to 22 carbon atoms, U is an unsaturated fatty acid having 16 to 22 carbon atoms) Which is an asymmetric triacylglycerol).
- Ninth is a lipid absorption inhibitor containing the asymmetric triacylglycerol described in the eighth as an active ingredient.
- a tenth aspect is an antiobesity agent containing the asymmetric triacylglycerol described in the eighth aspect as an active ingredient. Eleventh is a hyperlipidemia improving agent containing the asymmetric triacylglycerol described in the eighth as an active ingredient.
- a twelfth aspect is a food containing the agent according to any one of the eighth to eleventh aspects.
- a thirteenth aspect is a medicine containing the agent according to any one of the eighth to eleventh aspects.
- the oil-soluble substance selected in 1 is a glyceryl ether oil in which a long alkyl chain or alkenyl chain is ether-linked at the first or third position of glycerin.
- a fifteenth aspect is a lipid absorption inhibitor comprising the glyceryl ether lipid according to the fourteenth aspect as an active ingredient.
- Sixteenth is an antiobesity agent containing the glyceryl ether lipid described in the fourteenth as an active ingredient.
- Seventeenth is a hyperlipidemia improving agent containing the glyceryl ether lipid described in the fourteenth as an active ingredient.
- Eighteenth is a food containing the agent according to any one of the fourteenth to seventeenth.
- Nineteenth is a medicine containing the agent according to any one of the fourteenth to seventeenth aspects.
- SLS-type triacylglycerols of the present invention S is a symmetric triacylglycerol composed of a short-chain fatty acid having 2 to 6 carbon atoms, L is a long-chain fatty acid having 16 to 22 carbon atoms), LUU type and UUL-type triacylglycerol (L is a long-chain saturated fatty acid having 16 to 22 carbon atoms, U is an asymmetric triacylglycerol composed of an unsaturated fatty acid having 16 to 22 carbon atoms) or the first or third position of glycerin
- a substance selected from one or more glyceryl ether lipids with a long alkyl chain or alkenyl chain ether-linked at the position slowly inhibits lipase activity and is oil-soluble and can be added to any fats and oils. It is effective in preventing and treating obesity caused by excessive intake of fat and diseases caused by obesity.
- the oil-soluble substance SLS-type triacylglycerol which delays the hydrolysis by the lipase according to the first embodiment is characterized in that the fatty acid bound to the 1,3-position of the glycerol has an acetic acid having 2 carbon atoms and a caproic acid having 6 carbon atoms. And preferably acetic acid having 2 carbon atoms, and the 2-position is composed of palmitic acid having 16 carbon atoms, a fatty acid from palmitooleic acid to behenic acid having 22 carbon atoms, or elsic acid.
- the chain fatty acid may be either a saturated acid or an unsaturated acid, but is preferably a monounsaturated fatty acid.
- Some examples are 2P2 (triacylglycerol consisting of acetic acid in the 1- and 3-positions and palmitic acid in the 2-position), 202 (triacylglycerol consisting of acetic acid in the 1- and 3-positions and oleic acid in the 2-position), 2Li2 (l, triacylglycerol consisting of acetic acid at position 3 and linoleic acid at position 2), 2S2 (acetic acid at position 1,3, triacyldaricerol consisting of stearic acid at position 2), 2A2 (acetic acid at positions 1,3, 2-position triacylglycerol consisting of arachidic acid), 2B2 (1,3-position acetic acid, 2-position triacylglycerol consisting of behenic acid), 2E2 (1,3-position Is acetic acid, position 2 is triacylglycerol consisting of erucic acid), 4P4 (1,3 is butyric acid, position 2 is triacylglycerol is palm
- the SLS-type fats and oils are short-chain fatty acids at positions 1 and 3, they have a property that they are not susceptible to hydrolysis by lipase, and this SLS-type triacylglycerol is contained in fats and oils in an amount of 0.5 to 35% by weight.
- this SLS-type triacylglycerol is contained in fats and oils in an amount of 0.5 to 35% by weight.
- the mild inhibitory effect is preferred.Specifically, about 130%, and preferably about 120% of ingested fats and oils are hardly degraded. Ideal.
- the amount of the SLS-type triacylglycerol contained in the fat or oil is less than the lower limit, the expected effect is hardly obtained, and when the amount exceeds the upper limit, the flavor becomes poor and the effect becomes too strong.
- the SLS-type triacylglycerol of the present invention is generally used in combination with oils and fats derived from animals, plants and fish and short-chain fatty acids or lower alcohol esters thereof, for example, ethyl esters. Is mixed in an arbitrary mixture, and transesterified by a known method using a lipase having 1,3-position specificity.
- Vegetable oils and fats include, for example, soybean oil, rapeseed oil, palm oil, cottonseed oil, castor oil, corn oil, canola oil and the like, and animal oils and fats include beef tallow, lard, fish oil and the like.
- non-selective transesterification for example, using an alkaline catalyst such as sodium methylate, is possible.
- an alkaline catalyst such as sodium methylate
- Since it is possible to double the amount of the SSL triacylglycerol, which is a regioisomer, the LS triacylglycerol, it is effective. Is not very practical.
- the obtained SLS-type triacylglycerol is then subjected to ordinary processing such as distillation and fractionation and, if necessary, hardening to obtain a product having a purity of, for example, 70% or more.
- the SLS-type triacylglycerol of the present invention may be used as it is, or may be optionally mixed with other fats and oils.
- the mixing ratio differs depending on the expected effect and the system used.
- the mixing fat is not limited as long as it is an edible animal or vegetable fat.
- the SLS-type triacylglycerols of the present invention can be widely used for foods that usually contain fats and oils.
- cream margarine 'mayonnaise' dressing 'dairy products, emulsified foods such as vines, confectionery represented by chocolate, breads, hams, processed meats such as sausages, and fishery products such as rikamaboko's chikuwa It can be used without impairing the flavor and texture by adding it to other ingredients.
- the short-chain fatty acids in SLS-type triacylglycerols are somewhat weak in stability at high temperatures, they can of course be used for cooking and frying. It can also be used by adding it to water, juice, milk, tea, and soft drinks that do not contain fats and oils and are taken together with the above foods.
- the method of administering the lipase inhibitor, lipid absorption inhibitor, antiobesity agent, hyperlipidemia-improving agent, and a drug containing these of the present invention may be oral administration or parenteral administration.
- the active ingredient can be mixed with a solid or liquid pharmaceutical carrier suitable for administration methods such as oral administration, rectal administration and injection, and administered in the form of a formulation.
- a mixture of 50 parts of sunflower castor oil with an iodine value of 84 and 50 parts of ethyl acetate with a purity of 99.5% is mixed with a 1,3-position specific lipase (Novozaymes, Lipozyme RM-IM).
- the reaction oil was obtained by removing the esters by distillation at 220 ° C., and then the temperature was further raised to obtain 10 parts of 202 fraction having a purity of 83% at 250 ° C.
- the obtained 202 fractions are 1 part (202 purity about 0.8%), 5 parts (202 purity about 4.2%), 10 parts (202 purity about 8.3%), 50 parts ( The following lipase activity measurements were performed on the substituted system and the system of the 202 fraction itself (202 purity 83%).
- After sampling 80 mg of each fat and oil add 80 ml of phosphatidylcholine (Sigma), 5 mg of sodium tauroconoleate (Wako Pure Chemical Industries), 9 ml of 0.1 MTES buffer containing 0.1 M NaCl (PH 7), and ultrasonic oscillation
- the substrate emulsified for 1 minute was used as a substrate.
- porcine spleen lipase Sigma
- the reaction oil was obtained by mixing 50 parts of 98% pure triacetin and 50 parts of 98% pure ethyl oleate, and performing transesterification using 1,3-position specific lipase (Novozaymes Lipozyme RM-IM). After removing the esters by distillation at 220 ° C, the temperature was further raised to 250. C gave 50 parts of 220 fractions with a purity of 82%.
- Comparative pharmacology test 1 The obtained 220 fractions in soybean oil were 1 part (220 purity about 0.8%), 5 parts (220 purity about 4.1%), 10 parts (220 purity about 8.2%), 50 parts (The lipase activity was measured in the same manner as in the test example described above using the substituted system and the system of the 220 fraction itself (220 purity 82%). As shown in Table 1, it was determined that there was no effect of inhibiting the hydrolysis of lipase irrespective of the substitution amount of 220! ⁇ .
- a mixture of 55 parts of dried oil of castor oil with an iodine value of 84 and 45 parts of triacetin having a purity of 98% was subjected to random transesterification using sodium methylate.After neutralization and washing, about 60 parts of the reaction oil was removed. Obtained. The reaction oil was distilled at 250 ° C. to obtain 42 parts of a 220/202 mixed fraction having a purity of 87% (220 purity: about 57%, 202 purity: about 30%).
- the obtained 220/202 mixed fraction is 1 part in soybean oil (220 purity about 0.6%, 202 purity about 0.3%), 5 parts (220 purity about 2.9%, 202 purity about 1. 5%), 10 parts (220 purity about 5.7%, 202 purity about 3.0%), 50 parts (220 purity about 28.5%, 202 purity about 15%)
- the lipase activity was measured in the same manner as in the test example described above using the system of the 202 mixed fraction itself (220 purity 57%, 202 purity 30%). As shown in Table 1, even when the substitution amount of 220/202 was increased, no remarkable lipase hydrolysis inhibitory effect was observed.
- a mixture of 50 parts of oleaginous rapeseed oil having an iodine value of 84 and 50 parts of ethyl ethyl hexate having a purity of 98% is transesterified using a 1,3-position specific lipase (Novozaymes, Lipozyme RM-IM).
- the reaction oil was obtained by removing the esters by distillation at 220 ° C., and then further heated to obtain 15 parts of a 606 fraction having a purity of 78% at 258 ° C.
- mice Using the 202 fraction obtained in Production Example 1, a digestion and absorption test in mice was performed for about 2 months.
- the mice used were C57BLZ6J, which were pre-bred for 7 weeks from the age of 7 weeks for 1 week, and the diet composition was about 2 months for each group of 6 animals using the soybean oil group as a control with the compound diet shown in Table 2 in which the AIN-93G composition was partially improved.
- the animals were bred for a while, and weight change, feed efficiency and body fat percentage were measured. The body fat percentage was measured using an X-ray bone densitometer dedicated to experimental mice, PIXImus2 (GE Medicare). cal Systems).
- the oil-soluble substances LUU-type and UUL-type triacylglycerol that delay the hydrolysis by the lipase according to the second embodiment are fats that bind to the 1-position or 3-position of the glycerol.
- Acid is a saturated fatty acid, palmitic acid with 16 carbon atoms and up to 22 carbon atoms of behenic acid, and longer-chain fatty acids are preferred.
- 2nd and 3rd position (in case of LUU type) or 1st and 2nd position
- Fatty acids that bind to are also composed of fatty acids up to 16 carbon atoms in palmitooleic acid and up to erucic acid in 22 carbon atoms, and long-chain unsaturated fatty acids are converted from monounsaturated fatty acids to polyunsaturated fatty acids. Any unsaturated fatty acid may be used, but monounsaturation is preferred from the viewpoint of acidification stability when actually used.
- Some examples of such LUU-type or UUL-type triacylglycerols are SOO (l-stearic acid, 2,3 oleic acid), OOS (3rd stearic acid, 1,2 oleic acid ), SLiLi (1 stearic acid, 2,3 linoleic acid), SLnLn (1 stearic acid, 2,3 linolenic acid), BOO (1st position behenic acid, 2nd, 3rd position) Oleic acid), BLiO (behenic acid at the l-position, linoleic acid at the 2-position, oleic acid at the 3-position), and BOO (behenic acid at the 1st position, oleic acid at the 2nd and 3rd positions). ), OOB (behenic acid at position 3 and oleic acid at positions 1 and 2) are preferred.
- the LUU-type and UUL-type triacylglycerol fats and oils are difficult to be hydrolyzed by lipase because the fatty acid bonded to the 1st or 3rd position of the glycerol is a long-chain saturated fatty acid.
- a fatty acid bonded to the 1st or 3rd position of the glycerol is a long-chain saturated fatty acid.
- the mild inhibitory effect is preferred.Specifically, about 130%, and preferably about 120% of ingested fats and oils are hardly degraded. Ideal.
- the LUU-type and UUL-type triacylglycerols are generally any of oils and fats containing long-chain saturated fatty acids derived from animals, plants and fish, or esters thereof, and oils and fats containing long-chain unsaturated fatty acids. After mixing and mixing, it is obtained by transesterification using a lipase having 1,3-specificity by a known method.
- vegetable oils include soybean oil, rapeseed oil, palm oil, cottonseed oil, sunflower oil, corn oil, canola oil, and the like.
- Oils and fats include beef tallow, lard, fish oil and the like.
- non-selective transesterification for example, using an alkaline catalyst such as sodium methylate.
- an alkaline catalyst such as sodium methylate.
- the LUU-type and UUL-type triacylglycerols of the present invention may be used as they are, or may be optionally blended with other base fats and oils.
- the blending ratio varies depending on the expected effect and the system used, but there is no limitation as long as the base fat is an edible animal or vegetable fat.
- the LUU-type and UUL-type triacylglycerols of the present invention can be widely used for foods usually containing fats and oils.
- it can be added to emulsified foods such as cream 'margarine' mayonnaise 'dressing' dairy products, processed meats such as confectionery such as chocolate, bread, ham and sausage, and fishery foods such as kamaboko and chikuwa. Can be used without losing flavor and texture.
- the method of administering the lipase inhibitor, lipid absorption inhibitor, antiobesity agent, hyperlipidemia-improving agent, and a drug containing these of the present invention may be oral administration or parenteral administration.
- the active ingredient can be mixed with a solid or liquid pharmaceutical carrier suitable for administration methods such as oral administration, rectal administration and injection, and administered in the form of a formulation.
- a mixture of 50 parts of oil of sunflower castor oil with an iodine value of 84 and 50 parts of ethyl behenate with a purity of 95% is transesterified using 1,3-position specific lipase (Novozaymes, Lipozyme RM-IM). After removing the esters by distillation, 100 parts of hexane is crystallized at 5 ° C and fractionated to obtain 20 parts of LUUZUUL fraction with 70% purity. Thus, 30 parts of a LUL fraction having a purity of 78% were obtained.
- the obtained LUUZUUL fraction was placed in soybean oil in 1 part (LUUZUUL purity about 0.7%), 5 parts (LUUZUUL purity about 3.5%) and 10 parts (LUUZUUL purity about 7.0%), respectively.
- the following lipase activity measurements were performed on the exchanged system and the LUUZUUL fraction itself (LUUZUUL purity 70%).
- 80 mg of each fat and oil was sampled, and 80 mg of phosphatidylcholine (Sigma), 5 mg of sodium taurocholate (Wako Pure Chemical Industries), 9 ml of 0.1 MTES buffer containing 0.1 M NaCl (PH 7) were added, and then ultrasonication was performed. Emulsified with an oscillator for 1 minute was used as a substrate.
- a mixture of 40 parts of tribehen having an iodine value of 1, 60 parts of ethyl oleate having a purity of 98%, and 300 parts of hexane is mixed with 1,3-position specific lipase (Novozymes, Lipozyme RM-IM) to form an ester.
- the reaction oil is obtained by exchanging the solvent, the solvent is removed, the esters are removed by distillation, then 100 parts of hexane is added, and crystallization and fractionation are performed at a predetermined temperature to obtain a LLUZULL fraction having a purity of 72%. 15 parts and 10 parts of a 70% pure ULU fraction were obtained.
- Comparative pharmacology test 4 1 part (LLUZULL purity about 0.7%), 5 parts (LLUZULL purity about 3.6%), 10 parts (LLUZULL purity about 7.2%) of the LLUZULL fraction obtained in Comparative Production Example 3 in soybean oil
- the lipase activity was measured in the same manner as in the test example described above for the substituted system and the system of the LLUZULL fraction itself (LLUZULL purity: 72%).
- Table 4 when the substitution amount of LLU / ULL was increased, the effect of inhibiting the hydrolysis of lipase was recognized, but the effect was not so large as LUUZUUL.
- the ULU fraction obtained in Comparative Production Example 3 was soybean oil in 1 part (ULU purity of about 0.7%), 5 parts (ULU purity of about 3.5%), and 10 parts (ULU purity of about 7.0%).
- the lipase activity was measured in the same manner as in the test example described above for the substituted system and the system of the ULU fraction itself (ULU purity: 70%). As shown in Table 4, even when the substitution amount of ULU was increased, a remarkable lipase hydrolysis inhibitory effect was not recognized.
- mice used were preliminarily reared from C7BLZ6J at 7 weeks of age for 1 week, and the diet composition was about 2 months for each group of 6 using the soybean oil group as a control with the diet mixture shown in Table 5 in which the AIN-93G composition was partially modified.
- the animals were reared for a while, and changes in body weight, 'feed efficiency', and body fat percentage were measured.
- the body fat percentage was measured using an experimental mouse dedicated X-ray bone density measuring device, PIXImus2 (GE Medical Systems).
- the glyceryl ether lipid according to the third embodiment is composed of a lipid in which a long alkyl chain or a long alkenyl chain is ether-linked at the first or third position of glycerol, and has a structure easily recognized by lipase as a substrate. The presence of an ether bond at position 1 or 3 delays lipase hydrolysis.
- the alkyl and alkenyl chain lengths are not particularly limited, but those from C14 to C22 are realistic. There is no particular restriction on the 2nd position of dalicerol, but unsaturated fatty acids having an ester bond are preferred in order to suppress a rise in melting point.
- the glyceryl ether lipid has an ether bond at the 1-position or the 3-position, it is difficult to be hydrolyzed by lipase, and has a property.
- the glyceryl ether lipid is 0.5 to 30% by weight in the base fat or oil. %, Preferably 1 to 15% by weight, most preferably 1 to 10% by weight, if hydrolysis by lipase is moderated or delayed.
- the mild inhibitory effect is preferred.Specifically, about 130%, and preferably about 120% of ingested fats and oils are hardly degraded. Ideal.
- the glyceryl ether lipid is generally abundant in marine animal shark liver oil, and can be obtained by squeezing or extracting the glyceryl ether lipid with a solvent by distillation, fractionation, or the like. Marine animals include shrimp, squid, anchovy and the like, and sharks include giant shark. It is also included in teleost fish such as mullet.
- the obtained glyceryl ether lipid may be subjected to a treatment such as hydrolysis of an ester portion by an enzyme or hydrogenation depending on the use.
- the glyceryl ether lipid of the present invention may be used as it is, or may be optionally blended with another base oil and fat.
- the blended ratio varies depending on the expected effect and the system used.
- the base fat is not limited as long as it is an edible animal or vegetable fat.
- the glyceryl ether lipid of the present invention can be widely used for foods containing a normal fat or oil.
- a normal fat or oil for example, creams, margarines, mayonnaise, dressings, dairy products, tsutada milk foods, sweets such as chocolate, baked goods, processed meats such as ham and sausage, and marine products such as rikamaboko and chikuwa It can be used in engineered foods without sacrificing flavor or texture. It can also be used by adding it to water, juice, milk, tea, and soft drinks that do not contain fats and oils and are taken together with the above foods.
- the method for administering the lipase inhibitor, lipid absorption inhibitor, antiobesity agent, hyperlipidemia-improving agent, and a drug containing these of the present invention may be oral administration or parenteral administration.
- the active ingredient should be a solid suitable for the administration method such as oral administration, rectal administration and injection.
- they can be mixed with a liquid pharmaceutical carrier and administered in the form of a preparation.
- the following lipase activity was measured in a system in which the obtained glyceryl ether lipid fraction was replaced with 1, 5, and 10 parts in soybean oil, respectively, in the system of the glyceryl ether lipid fraction itself.
- After sampling 80 mg of each fat and oil add 80 ml of phosphatidylcholine (Sigma), 5 mg of tau sodium cholate (Wako Pure Chemical Industries), 9 ml of 0.1 M TES buffer containing 0.1 M NaCl (PH 7), and then add A substrate emulsified with a sonic oscillator for 1 minute was used as a substrate.
- mice Using the glyceryl ether lipid fraction obtained in Production Example 4, a digestion and absorption test was performed in mice for about 2 months.
- the mice used were preliminarily reared from C7BLZ6J at 7 weeks of age for 1 week, and the diet composition was controlled by the soybean oil group using the compound diet shown in Table 8 with a partial improvement of the AIN-93G composition. They were bred for 2 months, and the change in body weight 'feed efficiency' and body fat percentage were measured.
- the body fat percentage was measured using an experimental mouse dedicated X-ray bone density measuring device, PIXI mus2 (GE Medical Systems).
- lipase activity is gently inhibited, and it is oil-soluble and can be added to all edible fats and oils, and is effective in preventing and treating obesity due to excessive intake of fat and diseases caused by obesity. It has become possible to obtain a certain lipase inhibitor and an oil / fat composition containing the same.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/583,382 US20070191495A1 (en) | 2004-01-16 | 2004-12-24 | Lipase inhibitor |
CA2551119A CA2551119C (en) | 2004-01-16 | 2004-12-24 | Lipase inhibitor |
EP04807717A EP1704861A4 (en) | 2004-01-16 | 2004-12-24 | INHIBITOR OF LIPASE |
US12/662,405 US20100210723A1 (en) | 2004-01-16 | 2010-04-15 | Lipase inhibitor |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-008643 | 2004-01-16 | ||
JP2004008643 | 2004-01-16 | ||
JP2004-341343 | 2004-11-26 | ||
JP2004341343A JP2005225863A (ja) | 2004-01-16 | 2004-11-26 | リパーゼ阻害剤 |
JP2004345099A JP2006151875A (ja) | 2004-11-30 | 2004-11-30 | リパーゼ阻害剤 |
JP2004-345099 | 2004-11-30 | ||
JP2004-366955 | 2004-12-20 | ||
JP2004366955A JP2006169199A (ja) | 2004-12-20 | 2004-12-20 | リパーゼ阻害剤 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/662,405 Division US20100210723A1 (en) | 2004-01-16 | 2010-04-15 | Lipase inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005067913A1 true WO2005067913A1 (ja) | 2005-07-28 |
Family
ID=34799705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/019360 WO2005067913A1 (ja) | 2004-01-16 | 2004-12-24 | リパーゼ阻害剤 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20070191495A1 (ja) |
EP (2) | EP1704861A4 (ja) |
KR (1) | KR20060124679A (ja) |
CA (1) | CA2551119C (ja) |
WO (1) | WO2005067913A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007051338A1 (de) * | 2007-10-26 | 2009-04-30 | Müller-Enoch, Dieter, Prof. Dr. | Verwendung von substituierten Glycerinderivaten zur Herstellung einer pharmazeutischen Zubereitung zur Behandlung und zur Vorbeugung von Dyslipidämien |
CN102036559A (zh) * | 2008-05-19 | 2011-04-27 | 雀巢产品技术援助有限公司 | 降低动物脂质吸收的方法 |
KR100903705B1 (ko) * | 2008-12-17 | 2009-06-19 | 대한민국 | 저 포화, 무 트랜스 지방 함유 유지를 개발하기 위한 단계별 온도 시스템에서의 연속식 효소적 에스테르교환반응 |
US20120128770A1 (en) * | 2009-06-24 | 2012-05-24 | Kobenhavns Universitet | Treatment of insulin resistance and obesity by stimulating glp-1 release |
ES2667011T3 (es) | 2010-07-05 | 2018-05-09 | Beth Israel Deaconess Medical Center, Inc. | Monoacilgliceroles sn-2 y malabsorción lipídica |
CA3147249A1 (en) * | 2019-07-17 | 2021-01-21 | Baker Heart and Diabetes Institute | Compositions for maintaining or modulating mixtures of ether lipid molecules in a tissue of a human subject |
EP4232091A1 (en) * | 2020-10-26 | 2023-08-30 | Monash University | Lymph-targeting formulations |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1106681A (en) * | 1977-12-27 | 1981-08-11 | Vernon W. Trost | Low calorie fat substitutes |
US4598089A (en) | 1983-06-22 | 1986-07-01 | Hoffmann-La Roche Inc. | Leucine derivatives |
JPH0559392A (ja) * | 1991-09-03 | 1993-03-09 | Fuji Oil Co Ltd | 低吸収性油脂 |
JP2001040387A (ja) * | 1999-07-30 | 2001-02-13 | Showa Sangyo Co Ltd | 低カロリー液状油脂 |
JP2001523714A (ja) * | 1997-11-26 | 2001-11-27 | ザ、プロクター、エンド、ギャンブル、カンパニー | 皮膚発疹予防組成物 |
JP2002188096A (ja) * | 2000-10-12 | 2002-07-05 | Kanegafuchi Chem Ind Co Ltd | 新規なグリセリドおよびその製造法並びにその用途 |
JP2002524612A (ja) * | 1998-09-11 | 2002-08-06 | ダニスコ カルター アメリカ,インコーポレーテッド | カロリーが低減された可塑性脂肪組成物 |
JP2003119150A (ja) * | 2001-08-08 | 2003-04-23 | Oji Paper Co Ltd | リパーゼ阻害剤 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3492130A (en) * | 1966-11-21 | 1970-01-27 | Scm Corp | Hard butter compositions and method of production |
US4282265A (en) * | 1980-01-14 | 1981-08-04 | Bristol-Myers Company | Fat compositions for infant formulas |
US5427815A (en) * | 1993-12-10 | 1995-06-27 | Arco Chemical Technology, L.P. | Linked esterified alkoxylated polyols useful as reduced calorie fat substitutes |
US5654018A (en) * | 1994-06-24 | 1997-08-05 | Loders Croklaan B.V. | Behenic-rich triglycerides |
AR030954A1 (es) * | 2000-09-25 | 2003-09-03 | Hakim Nouri E | Fuentes de alimentacion para ninos |
JP3966689B2 (ja) | 2000-12-15 | 2007-08-29 | 株式会社ファンケル | リパーゼ阻害剤 |
JP2002275077A (ja) | 2001-01-11 | 2002-09-25 | Kanebo Ltd | リパーゼ阻害剤 |
-
2004
- 2004-12-24 CA CA2551119A patent/CA2551119C/en not_active Expired - Fee Related
- 2004-12-24 EP EP04807717A patent/EP1704861A4/en not_active Withdrawn
- 2004-12-24 EP EP11000095A patent/EP2298293A1/en not_active Withdrawn
- 2004-12-24 WO PCT/JP2004/019360 patent/WO2005067913A1/ja active Application Filing
- 2004-12-24 KR KR1020067013989A patent/KR20060124679A/ko not_active Application Discontinuation
- 2004-12-24 US US10/583,382 patent/US20070191495A1/en not_active Abandoned
-
2010
- 2010-04-15 US US12/662,405 patent/US20100210723A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1106681A (en) * | 1977-12-27 | 1981-08-11 | Vernon W. Trost | Low calorie fat substitutes |
US4598089A (en) | 1983-06-22 | 1986-07-01 | Hoffmann-La Roche Inc. | Leucine derivatives |
JPH0559392A (ja) * | 1991-09-03 | 1993-03-09 | Fuji Oil Co Ltd | 低吸収性油脂 |
JP2001523714A (ja) * | 1997-11-26 | 2001-11-27 | ザ、プロクター、エンド、ギャンブル、カンパニー | 皮膚発疹予防組成物 |
JP2002524612A (ja) * | 1998-09-11 | 2002-08-06 | ダニスコ カルター アメリカ,インコーポレーテッド | カロリーが低減された可塑性脂肪組成物 |
JP2001040387A (ja) * | 1999-07-30 | 2001-02-13 | Showa Sangyo Co Ltd | 低カロリー液状油脂 |
JP2002188096A (ja) * | 2000-10-12 | 2002-07-05 | Kanegafuchi Chem Ind Co Ltd | 新規なグリセリドおよびその製造法並びにその用途 |
JP2003119150A (ja) * | 2001-08-08 | 2003-04-23 | Oji Paper Co Ltd | リパーゼ阻害剤 |
Non-Patent Citations (7)
Title |
---|
GUILLON J. ET AL., PHARMACY AND PHARMACOLOGY COMMUNICATIONS, vol. 5, no. 5, 1999, pages 311 - 313 |
JANDACEK, R.J. ET AL., AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 45, 1987, pages 940 - 945 |
NAKABOU Y. ET AL.: "1,3-dicaproyl-2-stearoyl-glycerol no Rat Shokaki Kino eno Eikyo.", DIGESTION AND ABSORPTION., vol. 14, no. 2, 1991, pages 31 - 34, XP002992194 * |
See also references of EP1704861A4 |
SOFTLY B.J. ET AL.: "Composition of representative SALATRIUM fat preparations", J.AGRIC. FOOD CHEM., vol. 42, 1984, pages 461 - 467, XP009015469 * |
SOFTLY B.J. ET AL.: "Journal of Agricultural and Food Chemistry", 1994, AMERICAN CHEMICAL SOCIETY, pages: 461 - 467 |
SPENER F. ET AL.: "The internal absorption of glycerol trioctadecenyl ether.", BIOCHIMICA ET BIOPHISICA ACTA., vol. 152, 1968, pages 368 - 371, XP002992195 * |
Also Published As
Publication number | Publication date |
---|---|
EP2298293A1 (en) | 2011-03-23 |
US20070191495A1 (en) | 2007-08-16 |
US20100210723A1 (en) | 2010-08-19 |
EP1704861A4 (en) | 2009-11-25 |
CA2551119A1 (en) | 2005-07-28 |
EP1704861A1 (en) | 2006-09-27 |
CA2551119C (en) | 2013-02-12 |
KR20060124679A (ko) | 2006-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6762203B2 (en) | Oil composition | |
JP4685355B2 (ja) | 甘草疎水性成分含有油脂組成物の製造方法 | |
JP4031219B2 (ja) | 油脂組成物 | |
JP5155863B2 (ja) | 油脂組成物 | |
CA2381091C (en) | Fat composition | |
JP2007512407A (ja) | 共役リノール酸のジグリセライドの豊富な油脂組成物 | |
WO2007122801A1 (ja) | Gip分泌抑制剤 | |
US20100210723A1 (en) | Lipase inhibitor | |
JP2008069184A (ja) | 油脂組成物 | |
JP2003534356A (ja) | 短鎖、中鎖及び長鎖トリグリセリドから成る油組成物及び体重増加を減少させるためのその使用。 | |
JP4854253B2 (ja) | 脂質代謝改善用組成物 | |
Man et al. | Medium-chain triacylglycerols | |
JP5739180B2 (ja) | インスリン分泌促進用油脂組成物 | |
WO2011122389A1 (ja) | 糖尿病の予防又は治療用油脂組成物 | |
JP4634065B2 (ja) | アディポネクチン低下抑制剤 | |
JP4878494B2 (ja) | 食後血中インスリン上昇抑制剤 | |
JP2006151875A (ja) | リパーゼ阻害剤 | |
JP5066857B2 (ja) | 肝脂質低減剤 | |
JP2005225863A (ja) | リパーゼ阻害剤 | |
WO2007086397A1 (ja) | 脂質代謝改善用油脂組成物 | |
JP5211529B2 (ja) | 肝機能改善剤 | |
JP7295812B2 (ja) | リンパ循環改善剤 | |
JP2010241832A (ja) | アディポネクチン低下抑制剤 | |
JP2002029967A (ja) | 月経前症候群症状緩和用食用油脂組成物 | |
JP2014005258A (ja) | 脂質の消化吸収遅延剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10583382 Country of ref document: US Ref document number: 2007191495 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2551119 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067013989 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004807717 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004807717 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067013989 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 10583382 Country of ref document: US |